SlideShare a Scribd company logo
Dr. Laxmi Shrikhande
MD; FICOG ;FICMU
• Director-Shrikhande Fertility Clinic, Nagpur
• President Menopause Society, Nagpur
• National Corresponding Editor-The Journal of Obstetrics & Gynecology of India
• Senior Vice President FOGSI 2012
• Vice Chairperson ICOG
• Governing Council member ICOG 2012-2017
• Governing Council Member ISAR 2014-2019
• Governing Council Member IAGE for 3 terms
• Patron-Vidarbha Chapter ISOPARB
• Chairperson-HIV/AIDS Committee, FOGSI (2007-09)
• Received Best Committee Award of FOGSI
• Received Bharat excellence Award for women’s health
• President Nagpur OB/GY Society 2005-06
• Associate member of RCOG
• Member of European Society of Human Reproduction
• Visited 96 FOGSI Societies as invited faculty
• Delivered 3 orations
• Publications-Thirteen National & seven International
• Presented Papers in FIGO, AICOG, SAFOG, AICC-RCOG conferences
• Conducted adolescent health programme for more than 15,000 adolescent girls
Markers of Ovarian reserve
Dr Laxmi Shrikhande
Chief Consultant | Shrikhande fertility Clinic
Nagpur [Maharashtra] INDIA
What do we mean by ovarian reserve?
• term used to describe
• the functional potential of the ovary and
• reflects the number and quality of
oocytes within it
In ideal test
• should be predictive of conception (with or
without treatment) and
• should indicate how long current levels of
ovarian activity can be maintained before
ovarian ageing sets in
Ovarian reserve tests
Age
• Single most important factor
• At no cost
• Both quality and quantity
Natural Decline of Oocytes with Age
Decline in Ovarian reserve
• Age related decline in female fertility well
recognised
– Starts at 30,
– rapid decline after 37,
– virtually zero at 43.
• Due to decrease in
– Oocyte quantity
– Oocyte quality
Ovarian Reserve
Why we need markers of ovarian reserve ?
• Age of onset of decline in ovarian reserve is highly
variable
• Hence, the need for a marker to predict ovarian
reserve and fertility potential
• To identify young women with diminished ovarian
reserve
• To identify women with adequate OR even at the
age where natural fertility is lost (41 yrs)
Follicle Stimulating Hormone (FSH)
• Usually measured Day 2 or 3 of cycle
• Women with > 10 IU/l poor response to ART
• Women aged more than 30 with one value of
FSH > 14 IU/l do worse on IVF
• Variations within and between menstrual cycle
• Lab wise variation in values due to different
techniques.
• Spurious fall after hormone therapy.
Basal FSH
• Meta analysis of 37 studies
• Diversity in methodology and definition of poor
response
• Finding of high FSH don’t exclude her from IVF
treatment
Serum Oestradiol
• E2 alone of little value to asses ovarian reserve
• Combined E2 and FSH levels – better than E2
alone.
• E2 of < 20 pg/ml and > 80 pg/ml - higher
cancellation rate
FSH : LH ratio
• Can be used as an additional predictor for decreased
OR
• High ratio on D3 is associated with an inferior
outcome in IVF cycle
• Ratio is an early indicator of ovarian ageing
• No clinical use as OR marker
Inhibin B
• Hetero dimeric protein similar to AMH
• Levels > 45 pg/ml – poor response to
induction
• High false positive rate
• Not widely used nowadays.
AMH
• AMH is a glycoprotein
• Appears in females at puberty
• Produced by granulosa cells of pre-antral and small
antral follicles
• Reflects the growing pool of follicles in the ovary and
indirectly the entire pool of remaining eggs – the
“ovarian reserve”
Role of AMH
• Plays a role in the initial recruitment and
selection of the dominant follicle.
17
Poor
responder
Normal
responder
Hyper
responder
AMH helps define patient subgroups
<1ng 2-3.5ng >3.5ng
▪Highly correlates with ovarian response-
▪97%sensitivity in predicting poor response
▪98%accuracy in predicting normal response
Current Opin Obstet Gynae 2010 Jan
Hum Reprod Update 2010 Mar-Apr 16(2)
Fertil Steril 2010 Feb 93(3)
Individualised treatment plan
• Reduction of both excessive response and
cancellation of cycle
• Reduced risk of OHSS
• Increased pregnancy and live birth rates
• Cost reduction
Women who are overweight have 65% lower
AMH levels than thin women, indicating that
obesity may be associated with decreased
ovarian reserve and/or with ovarian dysfunction.
Obesity and AMH
AMH-benefits over other markers
• most sensitive predictor of ovarian response to
COH
• Not cycle dependant-can be measured any day
• Less cycle to cycle variation than FSH.
• Not altered after hormonal therapy.
• Not altered even after down regulation with
GNRH agonist.
• No inter observer variation as in AFC
AMH assay
• 2 assays-apply diff antibodies
• 1.DSL-Diagnostic Systems Laboratory
• 2. IOT-immunotech
• AMH levels are 40 % higher in IOT assay as
compared to DSL assay
• No international standard yet developed
AMH assay
• With the merger of both the companies in 2010
under Beckman Coulter led to the introduction of a
single new 2 step sandwich type enzymatic ,
microplate assay (the AMH gen II assay)
• AMH gen II assay is calibrated to the old IOT
standards and are thus comparable to IOT assay
• It has 2 fold greater sensitivity than the IOT assay
Pico AMH assay
• Has different calibration than Gen II assay
• Enhanced sensitivity over Gen II-enables
measurement of very low AMH concentrations
• Suitable for clinical use
• Need further studies in diff centres regarding its
stability
AMH – test
• Optimal storage and handling conditions
• Urgent need to prepare international reference
preparation to make test results comparable
• Until then we need to be careful in translating AMH
cut off values from studies to our clinical practice
AMH and its Interpretation
Ovarian Fertility
Potential
Pmol/L ng/ml
Optimal Fertility 28.6 to 48.5 4.0 to 6.8
Satisfactory Fertility 15.7 to 28.6 2.2 to 4.0
Low Fertility 2.2 to 15.7 0.3 to 2.2
Very low/ undetected 0.0 to 2.2 < 0.3
26
Role of AMH in women with cancer
• As it is secreted from granulosa cells AMH assay can
aid in diagnosis and follow up of ovarian granulosa
cell tumors
• Sensitivity ranges form 76-93 % for diagnosis of GCT
• Postop it can help as a marker for the efficacy of
surgery and for disease recurrence
Role of AMH in cancer survivour
• AMH assay before and after cancer treatment may
be useful to those women who are concerned about
fertility potential
• Levels usually drop during chemotherapy with
certain amount of recovery 2-6 months there after
• The main goal of AMH assay in young cancer
survivor would be to predict the long term
reproductive outcome
AMH-the best OR
• Best currently available marker in terms of sensitivity
and specificity as compared to AFC, FSH, E2 and
inhibin B
Clomiphene citrate challenge test CCCT
• Baseline FSH on D3
• CC 100 mg D5-9
• D10 FSH > 10 mIU/ml diminished OR
• Additional cost
• Pt compliance affect
• Absence of standardized abnormal test definitions
• Not an eligible OR test
Gonadotropin analog stimulation test GAST
• Leuprolide acetate SC 1mg
• Estradiol level on D2/3
• Increase of FSH and LH values twice the baseline
value or fall of estradiol
• Not eligible test
• Wide variety of analog doses,administration timing,
non standardization of threshhold values of
hormones tested
Exogenous FSH ovarian reserve test (EFORT)
▪ Baseline E2 and FSH
▪ Administer 300 IU FSH
▪ Recheck E 2 – 24 hours later : an increase in
E2 >30 pg/ ml
▪ Of no proven benefit
Fanchin et al 1994
Progesterone
• Doesn’t have any independent role in
assessment of ovarian reserve
• Early LH surge and elevation of P4 suggested
sign of poor ovarian reserve
Antral follicular count
• Count of total follicles measuring 2 to
5mm in both ovaries on Day 2/3 of
periods.
• Inter observer variation is a limitation.
• cycle to cycle variability
AFC
• 2 D real time TVS by 7 MHz transducer is adequate
• Manual counting on stored 3 D images
Ovarian volume
• D1xD2xD3x0.52
• Cut off 3.0 MI
• 3 D better than 2 D
• Inter observer variation
• Stand alone- not eligible
Ovarian Doppler
• Trans-vaginal pulse Doppler can assess ovarian
blood flow
• Some suggestion that high vascularity in early
follicular phase good prognostic sign
• Not of clinical value at present because of
different flow derived predictors
• women over 30 years of age
• women with a history of exposure to a confirmed
gonadotoxin, i.e., tobacco smoke, chemotherapy,
radiation therapy.
• women with a strong family history of early menopause
or premature ovarian failure.
• women who have had extensive ovarian surgery, i.e.,
cystectomy and unilateral oophorectomy.
Whom to subject for marker tests ?
Clinical application of OR test
• In general the average age at first child is 30 yrs
• Accurate OR testing will motivate some women to
start family early or go for oocyte frezing
• Alternatively it can reassure some women about
delaying childbirth
• Helps in individualisation of treatment plan-expectant
to ART
But we want
a baby !
Ovarian reserve markers helps
Helps counsel the patient in advance so that patients can
make an appropriate and informed choice.
Individualize expectation of oocyte yield
Cost of drug regimens
Discomfort to the patient expected
Risk of complications
Chances of disappointment
summary
• ORTs till date have modest predictive value for
pregnancy outcome as this is dependent on many
more factors apart from OR
• ORTs are indicative of ovarian reserve status in both
the quantitative and qualitative sense
• ORTs at best should be considered as screening
tests and not as diagnostic tests
• Treatment should not be denied based on these
tests to assumed ovarian aged woman
Conclusion
• Anti mullerian hormone(AMH) alone or better in
combination with antral follicular count (AFC) is
a better indicator of ovarian reserve than any
other hormonal or sonographic markers available
at present.
• Also a good predictor of response to ovulation
induction both poor as well as excessive
response.
My World of
sharing happiness!
Shrikhande Fertility Clinic
Ph- 91 8805577600
shrikhandedrlaxmi@gmail.com

More Related Content

What's hot

Recent 2018 ESHRE & ASRM evidence based guidelines for PCOS assement
Recent 2018 ESHRE & ASRM evidence based guidelines for PCOS assementRecent 2018 ESHRE & ASRM evidence based guidelines for PCOS assement
Recent 2018 ESHRE & ASRM evidence based guidelines for PCOS assement
Atef Darwish
 

What's hot (20)

ESHRE Guideline on Recurrent Pregnancy Loss (RPL)
ESHRE Guideline on Recurrent Pregnancy Loss (RPL)ESHRE Guideline on Recurrent Pregnancy Loss (RPL)
ESHRE Guideline on Recurrent Pregnancy Loss (RPL)
 
Optimizing IUI Outcome
Optimizing IUI OutcomeOptimizing IUI Outcome
Optimizing IUI Outcome
 
OVARIAN RESERVE
OVARIAN RESERVEOVARIAN RESERVE
OVARIAN RESERVE
 
Thin Endometrium
Thin EndometriumThin Endometrium
Thin Endometrium
 
Unexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil BharatiUnexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil Bharati
 
Iui - newer concepts
Iui  - newer conceptsIui  - newer concepts
Iui - newer concepts
 
Intrauterine Insemination UPDATE 2018
Intrauterine Insemination UPDATE 2018 Intrauterine Insemination UPDATE 2018
Intrauterine Insemination UPDATE 2018
 
Pcos Panel Discussion
Pcos Panel DiscussionPcos Panel Discussion
Pcos Panel Discussion
 
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiOvulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
 
Progestin-primed ovarian stimulation (PPOS) is a NEW DAW...
Progestin-primed ovarian stimulation (PPOS)                      is a NEW DAW...Progestin-primed ovarian stimulation (PPOS)                      is a NEW DAW...
Progestin-primed ovarian stimulation (PPOS) is a NEW DAW...
 
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati DhorepatilPCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
 
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain
OVARIAN RESERVE DIAGNOSIS & MANAGEMENT DR Sharda Jain
 
Endometriosis and art
Endometriosis and artEndometriosis and art
Endometriosis and art
 
Ovarian stimulation
Ovarian stimulationOvarian stimulation
Ovarian stimulation
 
Uterus Transplantation Utx (obstetric and gynecology)
Uterus Transplantation Utx (obstetric and gynecology) Uterus Transplantation Utx (obstetric and gynecology)
Uterus Transplantation Utx (obstetric and gynecology)
 
Diagnosis and Management of Poor Ovarian Reserve : Evidence & Practice
Diagnosis and Management of Poor Ovarian Reserve : Evidence & Practice Diagnosis and Management of Poor Ovarian Reserve : Evidence & Practice
Diagnosis and Management of Poor Ovarian Reserve : Evidence & Practice
 
Ulipristal acetate in treatment of fibroids
Ulipristal acetate in treatment of fibroidsUlipristal acetate in treatment of fibroids
Ulipristal acetate in treatment of fibroids
 
Ovarian Reserve Testing in Infertility Dr. Jyoti Agarwal Dr. Sharda Jain
Ovarian  Reserve Testing in Infertility Dr. Jyoti Agarwal Dr. Sharda JainOvarian  Reserve Testing in Infertility Dr. Jyoti Agarwal Dr. Sharda Jain
Ovarian Reserve Testing in Infertility Dr. Jyoti Agarwal Dr. Sharda Jain
 
Recent 2018 ESHRE & ASRM evidence based guidelines for PCOS assement
Recent 2018 ESHRE & ASRM evidence based guidelines for PCOS assementRecent 2018 ESHRE & ASRM evidence based guidelines for PCOS assement
Recent 2018 ESHRE & ASRM evidence based guidelines for PCOS assement
 
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTWHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
 

Similar to Markers of ovarian reserve presentation

Luteaal phase support lifecare centre
Luteaal phase support lifecare centreLuteaal phase support lifecare centre
Luteaal phase support lifecare centre
Lifecare Centre
 

Similar to Markers of ovarian reserve presentation (20)

AMH & its Clinical Implications.pptx
AMH & its Clinical Implications.pptxAMH & its Clinical Implications.pptx
AMH & its Clinical Implications.pptx
 
Ovarian Reserve - Testing & Management - Dr Dhorepatil Bharati
Ovarian  Reserve - Testing & Management - Dr Dhorepatil BharatiOvarian  Reserve - Testing & Management - Dr Dhorepatil Bharati
Ovarian Reserve - Testing & Management - Dr Dhorepatil Bharati
 
Early Ovarian Aging - Dr Dhorepatil Bharati
Early Ovarian Aging - Dr Dhorepatil BharatiEarly Ovarian Aging - Dr Dhorepatil Bharati
Early Ovarian Aging - Dr Dhorepatil Bharati
 
Markers of ovarian reserve
Markers of ovarian reserve Markers of ovarian reserve
Markers of ovarian reserve
 
Pearls of Wisdom in Infertility
Pearls of Wisdom in InfertilityPearls of Wisdom in Infertility
Pearls of Wisdom in Infertility
 
Ovarian hyper stimulation syndrome ohss
Ovarian hyper stimulation syndrome ohssOvarian hyper stimulation syndrome ohss
Ovarian hyper stimulation syndrome ohss
 
Female infertility 2017 : CRITICAL REVIEW OF Assessment & treatment in India ...
Female infertility 2017 : CRITICAL REVIEW OF Assessment & treatment in India ...Female infertility 2017 : CRITICAL REVIEW OF Assessment & treatment in India ...
Female infertility 2017 : CRITICAL REVIEW OF Assessment & treatment in India ...
 
Optimizing Fertility: Ovulation Induction in IUI - A Comprehensive Guide
Optimizing Fertility: Ovulation Induction in IUI - A Comprehensive GuideOptimizing Fertility: Ovulation Induction in IUI - A Comprehensive Guide
Optimizing Fertility: Ovulation Induction in IUI - A Comprehensive Guide
 
Luteaal phase support lifecare centre
Luteaal phase support lifecare centreLuteaal phase support lifecare centre
Luteaal phase support lifecare centre
 
Infertility presentation
Infertility presentation Infertility presentation
Infertility presentation
 
Ovulation induction protocols for unexplained infertility new advances 2019 f...
Ovulation induction protocols for unexplained infertility new advances 2019 f...Ovulation induction protocols for unexplained infertility new advances 2019 f...
Ovulation induction protocols for unexplained infertility new advances 2019 f...
 
Ovulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
Ovulation Induction in Different Case Scenario- Dr. Kaberi BanerjeeOvulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
Ovulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
 
Thyroid Disorders & infertility Dr jyoti Agarwal , Dr Sharda Jain
Thyroid Disorders & infertility Dr jyoti Agarwal , Dr Sharda Jain Thyroid Disorders & infertility Dr jyoti Agarwal , Dr Sharda Jain
Thyroid Disorders & infertility Dr jyoti Agarwal , Dr Sharda Jain
 
Fertility Challenges In Women With Biologically challenged Ovaries poor respo...
Fertility Challenges In Women With Biologically challenged Ovariespoor respo...Fertility Challenges In Women With Biologically challenged Ovariespoor respo...
Fertility Challenges In Women With Biologically challenged Ovaries poor respo...
 
Managing poor responders in IVF
Managing poor responders in IVFManaging poor responders in IVF
Managing poor responders in IVF
 
Anti mullerian hormone
Anti mullerian hormoneAnti mullerian hormone
Anti mullerian hormone
 
Effective Safe Superovulation.
Effective Safe Superovulation.Effective Safe Superovulation.
Effective Safe Superovulation.
 
Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal Dr. Jyoti Bh...
Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal  Dr. Jyoti Bh...Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal  Dr. Jyoti Bh...
Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal Dr. Jyoti Bh...
 
Diagnostic evaluation of the infertile female
Diagnostic evaluation of the infertile femaleDiagnostic evaluation of the infertile female
Diagnostic evaluation of the infertile female
 
Cos fertilis clinic 2015
Cos fertilis clinic 2015Cos fertilis clinic 2015
Cos fertilis clinic 2015
 

More from Dr.Laxmi Agrawal Shrikhande

More from Dr.Laxmi Agrawal Shrikhande (20)

5 Essential Steps for Menopause Hormone Therapy
5 Essential Steps for Menopause Hormone Therapy5 Essential Steps for Menopause Hormone Therapy
5 Essential Steps for Menopause Hormone Therapy
 
Understanding Metabolic Syndrome in PCOS: Symptoms, Risks, and Management
Understanding Metabolic Syndrome in PCOS: Symptoms, Risks, and ManagementUnderstanding Metabolic Syndrome in PCOS: Symptoms, Risks, and Management
Understanding Metabolic Syndrome in PCOS: Symptoms, Risks, and Management
 
Understanding Late Onset Menopause: Navigating Reproductive Changes with Age
Understanding Late Onset Menopause: Navigating Reproductive Changes with AgeUnderstanding Late Onset Menopause: Navigating Reproductive Changes with Age
Understanding Late Onset Menopause: Navigating Reproductive Changes with Age
 
Urinary Tract Infection in Pregnancy.pptx
Urinary Tract Infection in Pregnancy.pptxUrinary Tract Infection in Pregnancy.pptx
Urinary Tract Infection in Pregnancy.pptx
 
Unlocking Healthier Futures: A Guide to Pre-Conception Care
Unlocking Healthier Futures: A Guide to Pre-Conception CareUnlocking Healthier Futures: A Guide to Pre-Conception Care
Unlocking Healthier Futures: A Guide to Pre-Conception Care
 
Nourishing Your Body: Nutrition at Midlife
Nourishing Your Body: Nutrition at MidlifeNourishing Your Body: Nutrition at Midlife
Nourishing Your Body: Nutrition at Midlife
 
Understanding Fever in Pregnancy: What to Do Next | Expert Advice- Dr. Laxmi ...
Understanding Fever in Pregnancy: What to Do Next | Expert Advice- Dr. Laxmi ...Understanding Fever in Pregnancy: What to Do Next | Expert Advice- Dr. Laxmi ...
Understanding Fever in Pregnancy: What to Do Next | Expert Advice- Dr. Laxmi ...
 
Optimizing Nutrition in Midlife: Essential Guidance By Dr Laxmi Shrikhande
Optimizing Nutrition in Midlife: Essential Guidance By Dr Laxmi ShrikhandeOptimizing Nutrition in Midlife: Essential Guidance By Dr Laxmi Shrikhande
Optimizing Nutrition in Midlife: Essential Guidance By Dr Laxmi Shrikhande
 
GDM -what every obstetrician should know.pptx
GDM -what every obstetrician should know.pptxGDM -what every obstetrician should know.pptx
GDM -what every obstetrician should know.pptx
 
IVF Pregnancy -Is it different? A presentation by Dr Laxmi Shrikhande the lea...
IVF Pregnancy -Is it different? A presentation by Dr Laxmi Shrikhande the lea...IVF Pregnancy -Is it different? A presentation by Dr Laxmi Shrikhande the lea...
IVF Pregnancy -Is it different? A presentation by Dr Laxmi Shrikhande the lea...
 
Critical Analysis of ESHRE Guidelines on Unexplained Infertility
Critical Analysis of ESHRE Guidelines on Unexplained InfertilityCritical Analysis of ESHRE Guidelines on Unexplained Infertility
Critical Analysis of ESHRE Guidelines on Unexplained Infertility
 
Medical Management of Fibroids
Medical Management of FibroidsMedical Management of Fibroids
Medical Management of Fibroids
 
Medical Management of Fibroids Part 1
Medical Management of Fibroids Part 1Medical Management of Fibroids Part 1
Medical Management of Fibroids Part 1
 
Non Specific Musculoskeletal Pain
Non Specific Musculoskeletal PainNon Specific Musculoskeletal Pain
Non Specific Musculoskeletal Pain
 
Preview of Non Specific Musculoskeletal Pain
Preview of Non Specific Musculoskeletal PainPreview of Non Specific Musculoskeletal Pain
Preview of Non Specific Musculoskeletal Pain
 
Contraception where have we been and where are we going.pptx
Contraception where have we been and where are we going.pptxContraception where have we been and where are we going.pptx
Contraception where have we been and where are we going.pptx
 
Preview Contraception where have we been and where are we going
Preview Contraception where have we been and where are we goingPreview Contraception where have we been and where are we going
Preview Contraception where have we been and where are we going
 
Gestational Diabetes Mellitus.pptx
Gestational Diabetes Mellitus.pptxGestational Diabetes Mellitus.pptx
Gestational Diabetes Mellitus.pptx
 
Oral health & Pregnancy.pptx
Oral health & Pregnancy.pptxOral health & Pregnancy.pptx
Oral health & Pregnancy.pptx
 
Low amh what next
Low amh  what nextLow amh  what next
Low amh what next
 

Recently uploaded

Benefits of Dentulu's Salivary Testing.pptx
Benefits of Dentulu's Salivary Testing.pptxBenefits of Dentulu's Salivary Testing.pptx
Benefits of Dentulu's Salivary Testing.pptx
Dentulu Inc
 
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdfDemystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
SasikiranMarri
 
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptxASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
AnushriSrivastav
 
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptxBOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
AnushriSrivastav
 
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptxUrinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
AnushriSrivastav
 

Recently uploaded (20)

Chris Shade BS MEd MS LPC-Associate "Presume" (What Do I Do?)
Chris Shade BS MEd MS LPC-Associate "Presume" (What Do I Do?)Chris Shade BS MEd MS LPC-Associate "Presume" (What Do I Do?)
Chris Shade BS MEd MS LPC-Associate "Presume" (What Do I Do?)
 
Myopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptxMyopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptx
 
Benefits of Dentulu's Salivary Testing.pptx
Benefits of Dentulu's Salivary Testing.pptxBenefits of Dentulu's Salivary Testing.pptx
Benefits of Dentulu's Salivary Testing.pptx
 
💃Joint ❤89011-83002❤ #ℂALL #gIRLS Ludhiana Escorts by ✔️🍑💃Hotel #cALL #gIRLS...
💃Joint ❤89011-83002❤ #ℂALL #gIRLS Ludhiana Escorts  by ✔️🍑💃Hotel #cALL #gIRLS...💃Joint ❤89011-83002❤ #ℂALL #gIRLS Ludhiana Escorts  by ✔️🍑💃Hotel #cALL #gIRLS...
💃Joint ❤89011-83002❤ #ℂALL #gIRLS Ludhiana Escorts by ✔️🍑💃Hotel #cALL #gIRLS...
 
Occupational Therapy Management for Parkinson's Disease - Webinar 2024
Occupational Therapy Management for Parkinson's Disease - Webinar 2024Occupational Therapy Management for Parkinson's Disease - Webinar 2024
Occupational Therapy Management for Parkinson's Disease - Webinar 2024
 
Master the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga TrainingMaster the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga Training
 
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
 
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
Jaipur #ℂall #gIRLS Oyo Hotel 89O1183OO2 #ℂall #gIRL in Jaipur
 
VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...
VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...
VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...
 
Importance of Diet on Dental Health.docx
Importance of Diet on Dental Health.docxImportance of Diet on Dental Health.docx
Importance of Diet on Dental Health.docx
 
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptxNose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
 
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdfDemystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
 
Virtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdfVirtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdf
 
Digital Healthcare: The Future of Medical Consultations
Digital Healthcare: The Future of Medical ConsultationsDigital Healthcare: The Future of Medical Consultations
Digital Healthcare: The Future of Medical Consultations
 
The Docs PPG - 30.01.2024.pptx..........
The Docs PPG - 30.01.2024.pptx..........The Docs PPG - 30.01.2024.pptx..........
The Docs PPG - 30.01.2024.pptx..........
 
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptxASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
 
Call Girls in Jaipur (Rajasthan) call me [🔝89011-83002🔝] Escort In Jaipur ℂal...
Call Girls in Jaipur (Rajasthan) call me [🔝89011-83002🔝] Escort In Jaipur ℂal...Call Girls in Jaipur (Rajasthan) call me [🔝89011-83002🔝] Escort In Jaipur ℂal...
Call Girls in Jaipur (Rajasthan) call me [🔝89011-83002🔝] Escort In Jaipur ℂal...
 
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptxBOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
 
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptxUrinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
 
Enhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdfEnhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdf
 

Markers of ovarian reserve presentation

  • 1. Dr. Laxmi Shrikhande MD; FICOG ;FICMU • Director-Shrikhande Fertility Clinic, Nagpur • President Menopause Society, Nagpur • National Corresponding Editor-The Journal of Obstetrics & Gynecology of India • Senior Vice President FOGSI 2012 • Vice Chairperson ICOG • Governing Council member ICOG 2012-2017 • Governing Council Member ISAR 2014-2019 • Governing Council Member IAGE for 3 terms • Patron-Vidarbha Chapter ISOPARB • Chairperson-HIV/AIDS Committee, FOGSI (2007-09) • Received Best Committee Award of FOGSI • Received Bharat excellence Award for women’s health • President Nagpur OB/GY Society 2005-06 • Associate member of RCOG • Member of European Society of Human Reproduction • Visited 96 FOGSI Societies as invited faculty • Delivered 3 orations • Publications-Thirteen National & seven International • Presented Papers in FIGO, AICOG, SAFOG, AICC-RCOG conferences • Conducted adolescent health programme for more than 15,000 adolescent girls
  • 2. Markers of Ovarian reserve Dr Laxmi Shrikhande Chief Consultant | Shrikhande fertility Clinic Nagpur [Maharashtra] INDIA
  • 3. What do we mean by ovarian reserve? • term used to describe • the functional potential of the ovary and • reflects the number and quality of oocytes within it
  • 4. In ideal test • should be predictive of conception (with or without treatment) and • should indicate how long current levels of ovarian activity can be maintained before ovarian ageing sets in
  • 6. Age • Single most important factor • At no cost • Both quality and quantity
  • 7. Natural Decline of Oocytes with Age
  • 8. Decline in Ovarian reserve • Age related decline in female fertility well recognised – Starts at 30, – rapid decline after 37, – virtually zero at 43. • Due to decrease in – Oocyte quantity – Oocyte quality
  • 10. Why we need markers of ovarian reserve ? • Age of onset of decline in ovarian reserve is highly variable • Hence, the need for a marker to predict ovarian reserve and fertility potential • To identify young women with diminished ovarian reserve • To identify women with adequate OR even at the age where natural fertility is lost (41 yrs)
  • 11. Follicle Stimulating Hormone (FSH) • Usually measured Day 2 or 3 of cycle • Women with > 10 IU/l poor response to ART • Women aged more than 30 with one value of FSH > 14 IU/l do worse on IVF • Variations within and between menstrual cycle • Lab wise variation in values due to different techniques. • Spurious fall after hormone therapy.
  • 12. Basal FSH • Meta analysis of 37 studies • Diversity in methodology and definition of poor response • Finding of high FSH don’t exclude her from IVF treatment
  • 13. Serum Oestradiol • E2 alone of little value to asses ovarian reserve • Combined E2 and FSH levels – better than E2 alone. • E2 of < 20 pg/ml and > 80 pg/ml - higher cancellation rate
  • 14. FSH : LH ratio • Can be used as an additional predictor for decreased OR • High ratio on D3 is associated with an inferior outcome in IVF cycle • Ratio is an early indicator of ovarian ageing • No clinical use as OR marker
  • 15. Inhibin B • Hetero dimeric protein similar to AMH • Levels > 45 pg/ml – poor response to induction • High false positive rate • Not widely used nowadays.
  • 16. AMH • AMH is a glycoprotein • Appears in females at puberty • Produced by granulosa cells of pre-antral and small antral follicles • Reflects the growing pool of follicles in the ovary and indirectly the entire pool of remaining eggs – the “ovarian reserve”
  • 17. Role of AMH • Plays a role in the initial recruitment and selection of the dominant follicle. 17
  • 18. Poor responder Normal responder Hyper responder AMH helps define patient subgroups <1ng 2-3.5ng >3.5ng ▪Highly correlates with ovarian response- ▪97%sensitivity in predicting poor response ▪98%accuracy in predicting normal response Current Opin Obstet Gynae 2010 Jan Hum Reprod Update 2010 Mar-Apr 16(2) Fertil Steril 2010 Feb 93(3)
  • 19. Individualised treatment plan • Reduction of both excessive response and cancellation of cycle • Reduced risk of OHSS • Increased pregnancy and live birth rates • Cost reduction
  • 20. Women who are overweight have 65% lower AMH levels than thin women, indicating that obesity may be associated with decreased ovarian reserve and/or with ovarian dysfunction. Obesity and AMH
  • 21. AMH-benefits over other markers • most sensitive predictor of ovarian response to COH • Not cycle dependant-can be measured any day • Less cycle to cycle variation than FSH. • Not altered after hormonal therapy. • Not altered even after down regulation with GNRH agonist. • No inter observer variation as in AFC
  • 22. AMH assay • 2 assays-apply diff antibodies • 1.DSL-Diagnostic Systems Laboratory • 2. IOT-immunotech • AMH levels are 40 % higher in IOT assay as compared to DSL assay • No international standard yet developed
  • 23. AMH assay • With the merger of both the companies in 2010 under Beckman Coulter led to the introduction of a single new 2 step sandwich type enzymatic , microplate assay (the AMH gen II assay) • AMH gen II assay is calibrated to the old IOT standards and are thus comparable to IOT assay • It has 2 fold greater sensitivity than the IOT assay
  • 24. Pico AMH assay • Has different calibration than Gen II assay • Enhanced sensitivity over Gen II-enables measurement of very low AMH concentrations • Suitable for clinical use • Need further studies in diff centres regarding its stability
  • 25. AMH – test • Optimal storage and handling conditions • Urgent need to prepare international reference preparation to make test results comparable • Until then we need to be careful in translating AMH cut off values from studies to our clinical practice
  • 26. AMH and its Interpretation Ovarian Fertility Potential Pmol/L ng/ml Optimal Fertility 28.6 to 48.5 4.0 to 6.8 Satisfactory Fertility 15.7 to 28.6 2.2 to 4.0 Low Fertility 2.2 to 15.7 0.3 to 2.2 Very low/ undetected 0.0 to 2.2 < 0.3 26
  • 27.
  • 28. Role of AMH in women with cancer • As it is secreted from granulosa cells AMH assay can aid in diagnosis and follow up of ovarian granulosa cell tumors • Sensitivity ranges form 76-93 % for diagnosis of GCT • Postop it can help as a marker for the efficacy of surgery and for disease recurrence
  • 29. Role of AMH in cancer survivour • AMH assay before and after cancer treatment may be useful to those women who are concerned about fertility potential • Levels usually drop during chemotherapy with certain amount of recovery 2-6 months there after • The main goal of AMH assay in young cancer survivor would be to predict the long term reproductive outcome
  • 30. AMH-the best OR • Best currently available marker in terms of sensitivity and specificity as compared to AFC, FSH, E2 and inhibin B
  • 31. Clomiphene citrate challenge test CCCT • Baseline FSH on D3 • CC 100 mg D5-9 • D10 FSH > 10 mIU/ml diminished OR • Additional cost • Pt compliance affect • Absence of standardized abnormal test definitions • Not an eligible OR test
  • 32. Gonadotropin analog stimulation test GAST • Leuprolide acetate SC 1mg • Estradiol level on D2/3 • Increase of FSH and LH values twice the baseline value or fall of estradiol • Not eligible test • Wide variety of analog doses,administration timing, non standardization of threshhold values of hormones tested
  • 33. Exogenous FSH ovarian reserve test (EFORT) ▪ Baseline E2 and FSH ▪ Administer 300 IU FSH ▪ Recheck E 2 – 24 hours later : an increase in E2 >30 pg/ ml ▪ Of no proven benefit Fanchin et al 1994
  • 34. Progesterone • Doesn’t have any independent role in assessment of ovarian reserve • Early LH surge and elevation of P4 suggested sign of poor ovarian reserve
  • 35. Antral follicular count • Count of total follicles measuring 2 to 5mm in both ovaries on Day 2/3 of periods. • Inter observer variation is a limitation. • cycle to cycle variability
  • 36. AFC • 2 D real time TVS by 7 MHz transducer is adequate • Manual counting on stored 3 D images
  • 37.
  • 38. Ovarian volume • D1xD2xD3x0.52 • Cut off 3.0 MI • 3 D better than 2 D • Inter observer variation • Stand alone- not eligible
  • 39. Ovarian Doppler • Trans-vaginal pulse Doppler can assess ovarian blood flow • Some suggestion that high vascularity in early follicular phase good prognostic sign • Not of clinical value at present because of different flow derived predictors
  • 40. • women over 30 years of age • women with a history of exposure to a confirmed gonadotoxin, i.e., tobacco smoke, chemotherapy, radiation therapy. • women with a strong family history of early menopause or premature ovarian failure. • women who have had extensive ovarian surgery, i.e., cystectomy and unilateral oophorectomy. Whom to subject for marker tests ?
  • 41. Clinical application of OR test • In general the average age at first child is 30 yrs • Accurate OR testing will motivate some women to start family early or go for oocyte frezing • Alternatively it can reassure some women about delaying childbirth • Helps in individualisation of treatment plan-expectant to ART
  • 42. But we want a baby ! Ovarian reserve markers helps Helps counsel the patient in advance so that patients can make an appropriate and informed choice. Individualize expectation of oocyte yield Cost of drug regimens Discomfort to the patient expected Risk of complications Chances of disappointment
  • 43. summary • ORTs till date have modest predictive value for pregnancy outcome as this is dependent on many more factors apart from OR • ORTs are indicative of ovarian reserve status in both the quantitative and qualitative sense • ORTs at best should be considered as screening tests and not as diagnostic tests • Treatment should not be denied based on these tests to assumed ovarian aged woman
  • 44. Conclusion • Anti mullerian hormone(AMH) alone or better in combination with antral follicular count (AFC) is a better indicator of ovarian reserve than any other hormonal or sonographic markers available at present. • Also a good predictor of response to ovulation induction both poor as well as excessive response.
  • 45. My World of sharing happiness! Shrikhande Fertility Clinic Ph- 91 8805577600 shrikhandedrlaxmi@gmail.com